Joint Formulary & PAD

Adalimumab - Inflammatory bowel disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

PAD Profile

ChemicalSubstance :
Adalimumab
Indication :
Inflammatory bowel disease
Group Name :
Keywords :
IBD, biologics, biosimilars, Sequential use of biologic medicines, TNF alpha inhibitor, Cytokine modulator, Crohn's disease, Ulcerative Colitis, UC, immunomodulators
Brand Names Include :
Humira, Amgevita, Imraldi, Hulio, Hyrimoz, Mylan, Yuflyma, Idacio
Important Information :
For UC & CD. Adults only. Prescribe by brand.
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
4

Other Indications

Below are listed other indications that Adalimumab is used to treat.

Committee Recommendations (2)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway, which is to be found on the IBD guidelines page.

The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Https://www/gov/uk/drug-safety-update/biosimilar-products

Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.